Angelalign Technology Inc (6699) Fair Value & Analysis
Healthcare · HK · Market cap HK$12.2B
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 3 days ago
Share price +25.7% over the past month.
A strong business, but screening 78% overvalued on our models.
What matters now
- A high-quality business (quality 75/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (HK$24.84). The favourable scenario is already priced in.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$43.55 – HK$435.70 · fair‑value band HK$16.72 – HK$24.84 · the HK$94.40 price screens above the HK$20.78 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Angelalign Technology Inc (6699) currently trades at HK$94.40, while our model-based Fair Value estimate is HK$20.78, implying the stock looks roughly 78.0% overvalued today. The Quality Score stands at 75/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Angelalign Technology Inc generated revenue of HK$370M at a net margin of 7.7%. Revenue grew 41.6% year over year. It earns a return on equity of 5.4%. The balance sheet holds a net cash position of HK$775M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$16.72 (bear case) to HK$24.84 (bull case); at HK$94.40, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades near its 52-week high and 85% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -46% fair-value upside, at -78%, 6699 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (HK$57.59) versus Dividend Discount (HK$12.10). Highest evidence: Growth DCF (80).
Notify me when 6699 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 75 · Market factors (momentum, volatility) 73
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Angelalign Technology Inc., an investment holding company, researches and designs, manufactures, sells, and markets clear aligner treatment solutions in the People's Republic of China and internationally.
Full company description
Angelalign Technology Inc., an investment holding company, researches and designs, manufactures, sells, and markets clear aligner treatment solutions in the People's Republic of China and internationally. The company's products include Angel Aligner Pro and Angel Aligner Select, a custom made removable clear orthodontic aligners that move the patient's teeth into the proper position over time; Angel Aligner KiD, a early orthodontic solution from prevention to treatment; and Angel Aligner Retainer. It also provides orthodontics and cosmetic dentistry services, and other dental services through its dental clinics. In addition, it sells intraoral scanners, brackets, and other products to hospitals, dental clinics and distributors; and engages in investing activities. Angelalign Technology Inc. was founded in 2003 and is headquartered in Shanghai, China. Angelalign Technology Inc. is a subsidiary of CareCapital Orthotech Limited.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Angelalign Technology Inc reported revenue of HK$2.6B in FY2025 versus HK$1.3B in FY2021, a compound +19.5%/yr. Reported net income was HK$199M in FY2025, compounding −8.6%/yr from FY2021.
6699 screens 78% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 202 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $401.27 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €164.40 | €68.55 | -58% |
| Medline Inc MDLN | $35.50 | $30.15 | -15% |
| Becton, Dickinson and Company BDX | $181.41 | $100.46 | -45% |
| Alcon Inc ALC | $73.58 | $39.78 | -46% |
| ResMed Inc RMD | $226.00 | $187.89 | -17% |
| West Pharmaceutical Services, Inc WST | $352.29 | $141.58 | -60% |
| Sartorius Stedim Biotech S.A DIM | €180.30 | €48.88 | -73% |
| Coloplast A/S COLOB | kr 429.70 | kr 382.22 | -11% |
| Gan & Lee Pharmaceuticals., a biopharmaceutical company, 603087 | ¥77.48 | ¥27.22 | -65% |
Compare Angelalign Technology Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Angelalign Technology Inc (6699) overvalued or undervalued?
What is the fair value of 6699?
What is the quality score of 6699?
What is the revenue of Angelalign Technology Inc (6699)?
What is the net profit margin of 6699?
Does Angelalign Technology Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Angelalign Technology Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.